SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: OCT1 activity was reported to correlate with the sensitivity of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) [22–24] and the expression of SLC22A1 variants may affect the response of HCC to sorafenib [25].